CD30 is a member of the tumor necrosis factor receptor family. It belongs to a type I transmembrane protein. It is overexpressed in Hodgkin’s lymphoma and gradual large cell tumor lymphoma, and is low in T cells and B cells activated in non-case conditions Surface, while normal cells do not express. Early studies have shown that CD30 is involved in cell activation and differentiation, signal transduction such as NF-kB, and T cell immune activation. Current studies have confirmed that CD30 is closely related to cell proliferation and death. Its intracellular part can interact with multiple members of the TNFR-related factor family, which can mediate cell apoptosis through the JNK and p38 pathways, and mediate cell activation through the NF-kB pathway. After CD30 is activated, its extracellular part is quickly degraded by proteases to form soluble CD30. CD30 is commonly expressed on the surface of HL and ALCL cells and can be used as a potential target for antibody targeted therapy. This product is a second-generation CAR lentiviral expression vector targeting CD30, which can be used for in vivo and in vitro pharmacodynamic experiments.

Product name: Lenti-EF1a-CD30-2nd-CAR-EGFRt

Promoter: EF1a [1]

Intracellular co-activation signal: 4- 1 BB /CD3Zata

Resistance gene: Amp

Tag: EGFRt [2]



1. Compared with the CMV promoter, EF1a can be continuously expressed in immune cells, so it can significantly extend the expression of CAR in T cells.

2. EGFRt intercepts domain III and domain IV of wild-type EGFR. This truncated EGFRt has no intracellular signal and will not transmit other signals to T cells. At the same time, these two domains are cetuximab Recognizing the epitope and expressing the epitope on T cells can not only be used as CAR-T screening markers, but also add a safety switch for clinical research. Related flow cytometry antibodies can be inquired ( iCARTab, CAT# IAB001A )